

Dr. Tomas Salmonson  
European Medicines Agency  
30 Churchill Place  
Canary Wharf  
London  
E14 5EU  
United Kingdom

Dear CHMP Chairman,

I would like to inform you that, at this point of time, Nordic Group BV has taken the decision to withdraw the application for the extension of indication for Teysuno, to use Teysuno in combination with a platinum-based regimen in the treatment of advanced gastric cancer.

This withdrawal is based on the following reasons:

- *The Rapporteur considers in the Preliminary RMP Update Assessment Report that the data provided do not allow to conclude on a positive benefit risk balance for the combination S1-oxaliplatin at this time*

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMEA website.

All necessary documents have been removed with this consolidated sequence.

Should you have any further question, please do not hesitate to contact me.

